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ABSTRACT 
The risk of premature mortality is increased in people with epilepsy. The reasons for this and 
how it may relate to epilepsy aetiology remain unclear. The National General Practice Study of 
Epilepsy is a prospective, community-based cohort that includes 558 people with recurrent 
unprovoked seizures and almost 25 years of follow-up. In this study the underlying and 
immediate causes of death are described as well as their relationship to epilepsy aetiology and 
epilepsy-related causes of death. Predictors of mortality were examined using adjusted Cox 
proportional hazards models, with a particular emphasis on the psychiatric and somatic 
comorbidities of epilepsy. We found that the three most common underlying causes of death 
were neoplasm, cardiovascular and cerebrovascular disease, accounting for the majority of 
deaths (58.8% or 111/189) while epilepsy-related causes accounted for 3.2% (6/189) of deaths. 
Pneumonia was the most common immediate causes of death and accounted for 31.2% (59/189) 
of deaths. Overall, in 22.8% of individuals, the underlying causes of death was directly related to 
the epilepsy aetiology, although this differed significantly depending on whether the death 
occurred within two years of the index seizure or later [percent ratio=4.28 (95% confidence 
interval: 2.63, 6.97)]. The adjusted models demonstrated that International Classification of 
Diseases-10 chapters 2, 4, 13, 17 and 19 / 20 were significant predictors of mortality. Specific 
comorbidities associated with increased mortality were: primary cerebral neoplasm, non-cerebral 
neoplasm, substance abuse, dementia, Parkinson’s disease and traumatic brain injury. Our 
findings suggest particular lines of investigation and intervention for the future which may serve 
to stem the tide of premature mortality in epilepsy. 
 
KEYWORDS: Epilepsy, mortality, cause of death, comorbidity 
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ABBREVIATIONS:  
Cause of death (COD) 
Confidence interval (CI) 
General practitioners (GP) 
Hazard ratio (HR) 
International Classification of Diseases (ICD) 
Interquartile range (IQR) 
National General Practice Study of Epilepsy (NGPSE) 
People with epilepsy (PWE) 
Proportionate mortality ratio (PMR) 
Sudden unexplained death in epilepsy (SUDEP) 
United Kingdom (UK)   
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INTRODUCTION 
Recent work has highlighted that PWE suffer from premature mortality relative to the general 
population. This has been shown in high-income countries such as the UK
1
, USA
2
, Sweden
3
 and 
Iceland
4
 as well as low- to middle-countries such as Bolivia
5
, India
6
 and China.
7
 The reasons for 
this are not readily apparent. Prior studies have described the distribution of the CODs in PWE 
but few distinguished between underlying and immediate causes.
7-13
 There is a paucity of data 
examining the relationship between epilepsy aetiology and COD.
14, 15
 There also have been 
attempts to describe predictors of premature mortality in people, including non-adherence to 
antiepileptic drugs, psychiatric disorders, cognitive impairment and age
11, 16, 17
 but there have 
been no comprehensive assessments of the role of the full spectrum of somatic and psychiatric 
comorbidities of epilepsy in predicting mortality in a cohort of PWE.  
We describe the underlying and immediate CODs seen in a large community-based 
prospective cohort of PWE with almost 25 years of follow-up, inquire into the relationship 
between underlying COD and epilepsy aetiology as well as examine for predictors of mortality, 
with a particular emphasis on the somatic and psychiatric comorbidities of epilepsy. 
 
MATERIAL AND METHODS 
The NGPSE is a longitudinal cohort study of incident epileptic seizures with almost 25 years of 
follow-up, the methods of which have been previously described.
1, 18
 Briefly, the subjects of the 
NGPSE were initially identified between June 1984 and October 1987 by 275 participating GPs 
from across the UK who had been asked to report any person of any age with newly suspected 
epileptic seizures. A diagnostic panel subsequently reviewed all potential participants and 
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identified those with definite or probable/possible epileptic seizures. Of the initial 1195 people 
registered by their GP, the diagnostic panel concluded that 792 (66.3%) had had epileptic 
seizures. The remaining individuals were diagnosed with either febrile seizures (n=220), pre-
existing epilepsy or neonatal seizures (n=104), or no clear history of epileptic seizures (n=79) 
and have been excluded from the present report.  
For the purposes of this report we further excluded those with a single recorded epileptic 
seizure (and at least 12 months of follow-up) as well as those with acute symptomatic seizures 
(occurring within 90 days of a precipitating cerebral injury, as per the consensus during the 
NGPSE’s initial design). This resulted in a cohort of 558 individuals with recurrent unprovoked 
epileptic seizures. 
Following the initial assessment between 1984 and 1987, there were approximately 
annual follow-ups by NGPSE investigators with each individual’s GP up to 1997 after which 
there were two more follow-ups, in 2001 and 2009. In general, no direct contact was made by 
NGPSE investigators with individual study participants. With the initial assessment and each 
subsequent follow-up, data were collected on basic demographics and features of each person’s 
seizures. In addition to these epilepsy-related queries, additional information was sought on all 
possible somatic and psychiatric comorbidities. This final set of queries used pointed questions 
about the presence of a number of conditions which were considered especially relevant at the 
time of the NGPSE’s initial design (meningitis/encephalitis, stroke, intra-cranial surgery, head 
injury with loss of consciousness, alcohol or drug abuse) but also instructed GPs to record any 
additional condition(s) the individual may have. This information was elicited from the GPs on 
12 occasions, up until 2001. Following this, after the passing of the UK Data Protection Act of 
1998 and the Health and Social Care Act of 2001, new individual consent requirements were 
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applied to the NGPSE, requirements that created insurmountable barriers to the continued 
collection of comorbidity data. A single study author (MRK) reviewed the reported 
comorbidities and coded the associated ICD-10 chapter 
19
 as well as the date when it was first 
reported.  
All individuals in the NGPSE have been flagged at the UK National Health Service 
(NHS) Information Centre. The study investigators are therefore notified whenever any person 
dies and are sent a copy of the death certificate. This ensures complete mortality ascertainment, 
assuming that the subject dies within the territorial boundaries of the UK, or that the NHS was 
notified of their death if they died elsewhere. Each death certificate respects the World Health 
Organisation’s recommended format and includes fields for recording up to three CODs20 Each 
death certificate also includes field II (i.e. “Other significant conditions contributing to the 
death…”). All deaths occurring up until the 5th October 2009 are included in this report. 
 Only selected data related to the distribution of CODs from this cohort have been 
previously reported.
1, 21, 22
 Previously, our research group also did not explicitly distinguish 
between underlying and immediate COD but instead identified one COD based upon the clinical 
judgement of the investigators while reviewing the contents of the death certificate. In the 
present study, we present complete COD data and strictly distinguish between underlying COD 
and immediate COD. The distinction between these two types of COD reflects our understanding 
of which condition initiated a series of events leading to death (i.e. the underlying COD) versus 
the condition which occurred only just prior to death (i.e. immediate COD). The Sixth Decennial 
International Revision Conference of the World Health Organisation resolved that the underlying 
COD be reported as the main COD in all official reporting.
20, 23
 Care therefore was taken for the 
purposes of this study by one author (MRK) to record the underlying COD according the to the 
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“General Principle” and selection rules as laid out in the ICD-10 manual.20 As such, pneumonia 
and pulmonary embolism were considered immediate CODs unless there were no other CODs 
listed on the death certificate, in which case they were recorded as “pneumonia or pulmonary 
embolism not otherwise specified”. Cardiac or respiratory failure is a mode of death, as 
described in the ICD-10, and not a COD; if no other condition was listed on the death certificate, 
the underlying COD was coded as “Other”. Vascular dementia was coded as dementia rather 
than cerebrovascular disease. Each COD was described as a PMR, where the numerator is the 
number of deaths due to a particular COD and the denominator is the total number of deaths in 
the same population and period.
24
  
The underlying epilepsy aetiology was characterized for all individuals. This was done 
using the information provided by GPs up until the timing of the diagnostic panel. One study 
author (MRK), unaware of any other characteristic of each person including the timing of their 
death, determined whether the underlying COD was directly related to the epilepsy aetiology for 
that individual (e.g. both due to a primary cerebral neoplasm or cerebrovascular disease).. Death 
from an external cause was generally not considered related to a post-traumatic epilepsy unless 
these were the same event. It was assumed conservatively that death from dementia was not 
related to cerebrovascular disease.  
Statistical analyses 
Any differences in proportions were tested using two-sided Fisher’s exact test. A Holms-
Bonferroni correction was used to control for the effect of multiple comparisons.
25
 Continuous 
variables are presented as median (IQR) due to heavily skewed distributions rendering means 
difficult to interpret. 
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 Cox proportional hazards regression were used to model associations between each ICD-
10 comorbidity chapter and all-cause mortality. Additional comorbidities that were only listed on 
the death certificates were not included in this analysis since this would have created a 
systematic source of error (i.e. information bias) differential to those who have, versus have not, 
died. Each ICD-10 chapter was first regressed using a simple model where age at the time of the 
index seizure (the event that lead to their presenting to medical attention; categorized into 
approximate quartiles) and sex were included as covariates. ICD-10 chapters found to have a p-
value <0.10 in the simple model were included in the fully adjusted model, along with age at the 
time of the index seizure, subject sex and early seizure remission (defined as an absence of 
seizures more than one year after the index event). The period at risk for each subject began with 
the time of the index seizure and ended with the time of death or, if alive, the 5
th
 October 2009. 
With the exception of chapters 16 and 17 which are by definition congenital and therefore 
present at the beginning of the period at risk, each ICD-10 chapter was treated as a categorically 
time-varying covariate with the exposure to each chapter beginning when it was first reported to 
the NGPSE investigators. These analyses allowed us to account for differences in the duration of 
exposure to each comorbidity. Schoenfeld residuals were used to confirm that the proportionality 
assumption was met for each regression model.
26
 The assumption was considered violated when 
the global test was associated with a p-value <0.05. The categorical covariate early epilepsy 
remission (defined as no recurrent seizures after one year of follow up) was transformed to vary 
linearly with time in order to correct for a violation of the proportionality assumption. 
STATA/SE, version 12.0 (StataCorp LP, College Station, Texas, USA) was used to 
conduct all statistical analyses.  
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The NGPSE was approved by the National Research Ethics Committee (REC Reference: 
07/H0720/160); individual informed consent was again not required by the ethics committee. 
 
RESULTS 
The clinical characteristics and demographics of the cohort are presented in Table 1. Median age 
at the time of the index seizure was 24.4 years (IQR: 13.8, 56.1) and 291 (52%) were men. There 
were 190 deaths during the follow-up period (i.e. up to 5
th
 October 2009) although the death 
certificate was not available for one person. Median age at last follow-up was 40.9 years (IQR: 
33.3, 51.1) for those still alive at last follow-up and 74.8 years (59.1, 83.1) for those who died 
(i.e. their age at the time of death). One hundred eighty-three (32%) individuals did not have any 
recurrent seizures after 1 year since the index seizure (i.e. early epilepsy remission). Median 
duration of follow-up was 23.9 years (IQR: 23.0, 24.7) for those still alive at last follow-up.  
The distribution of the underlying CODs is depicted in Fig. 1A. A majority of deaths 
were due to non-cerebral neoplasm, cardiovascular or cerebrovascular disease (58.8% or 111 of 
189) while external causes and epilepsy-related (e.g. SUDEP or status epilepticus) accounted for 
only 4.2% (8 of 189) and 3.2% (6 of 189), respectively. Fifty-two percent of the non-cerebral 
neoplasms were responsible for an individual’s epilepsy as a result of metastatic disease.  
The distribution of the immediate CODs is depicted in Fig. 1B. Pneumonia was the most 
common immediate COD and accounted for 31.2% (59 of 189) of all deaths. Among individuals 
whose immediate COD was pneumonia, the underlying CODs were: 13 (22.0%) with 
cerebrovascular disease, 10 (17.0%) with other, eight (13.6%) with non-cerebral neoplasm, seven 
(11.9%) with congenital neurological disorder, five (8.5%) with cardiovascular disease, five 
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(8.5%) with neurodegenerative disease and two (3.4%) were epilepsy-related. For nine (4.8%) 
individuals who died of pneumonia, an underlying COD was not indicated on the death 
certificate. 
 In Fig. 2, the underlying CODs are stratified by timing of death (Fig. 2A) as well as age 
at the time of the index seizure (Fig. 2B) and time of death (Fig. 2C). After correcting for the 
effect of multiple comparisons, there were no evident differences in the proportions of each 
underlying COD when stratified by timing of death (≤2 years versus >2 years after the index 
seizure) with non-significant p-values throughout (Supplementary Table 1). People aged less 
than 60 years at the time of the index seizure as well as those aged less than 60 years at the time 
of death were more likely to die of primary cerebral neoplasm [15.1% versus 0.9% (p-value 
<0.010), and 21.3% versus 1.4% (p-value <0.010), respectively] or a congenital neurological 
disorder [9.6% versus 0.9% (p-value=0.048), and 12.8% versus 1.4% (p-value=0.003), 
respectively] but were less likely to die of cerebrovascular disease [2.7% versus 26.7% (p-value 
<0.010) and 4.3% versus 21.8% (p-value <0.028), respectively] with a similar but non-
significant trend in cardiovascular disease (Fig. 2B-2C and Supplementary Table 1). People aged 
less than or equal to 60 years at the time of death were also more likely to die of external causes 
(12.8% versus 1.4%, p-value=0.027). 
We found that in 22.8% (43 of 189) of deaths, the underlying COD was directly related to 
the individual’s epilepsy aetiology (43.4% if the 90 individuals with idiopathic/cryptogenic 
epilepsy are excluded). This proportion was as high as 57.5% during the first 2 years of follow-
up (69.7% if the seven individuals with idiopathic/cryptogenic epilepsy are excluded), 
decreasing over time to as low as 6.0% at >15 years of follow-up. (Fig. 3 with further details in 
Supplementary Table 2). Overall, among people dying within two years of their index seizure, 
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there was a more than four-fold greater chance that the cause of their epilepsy was directly 
related to their underlying COD [percent ratio (95% CI) =4.28 (2.63, 6.97); p-value<0.0001] as 
compared to people who died more than two years after their index seizure. The epilepsy 
aetiologies of the 190 individuals who died are listed in Supplementary Table 3. 
The results of our survival analyses examining for predictors of mortality are presented in 
Tables 2 and 3. Age was the strongest predictor of death, where people aged 60 years or more at 
the time of the index seizure were on average 67 times more likely to die than people aged less 
than 15 years [adjusted HR: 66.92 (95% CI: 32.55, 137.59)]. Surprisingly, male sex was found to 
be protective, with a 30% decrease in the risk of death (adjusted HR: 0.69 (95% CI: 0.51, 0.93). 
There was no evidence that early epilepsy remission was predictive of mortality.  
Of the comorbidities of epilepsy, ICD chapters 2 (neoplasms), 4 (endocrine, nutritional 
and metabolic diseases), 13 (diseases of the musculoskeletal system and connective tissue), 17 
(congenital malformations, deformations and chromosomal abnormalities) and 19/20 (injury, 
poisoning and certain other consequences of external causes / external causes of morbidity and 
mortality) were significant predictors of mortality (Table 2). ICD chapter 13 was the only 
chapter whose presence predicted a decreased risk of mortality [adjusted HR: 0.42 (95% CI: 
0.19, 0.91)].  
 Examining the constituents of selected ICD chapters, primary cerebral and non-cerebral 
neoplasms, substance abuse, dementia, Parkinson’s disease, cerebrovascular disease and 
traumatic brain injury were significant and independent predictors of mortality (Table 3). 
  
DISCUSSION 
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The NGPSE is one of the few and largest prospective community-based cohorts of PWE with 
almost 25 years follow-up examining the risk and determinants of mortality among PWE.
2, 4, 27
 
Prior analyses of the NGPSE have reported the overall SMR for all-cause mortality, stratified by 
age group, timing after index seizure and epilepsy aetiology, as well as SMRs for selected 
CODs.
1, 21, 22
 We report three new main findings. First, we describe the complete distribution of 
CODs, distinguishing between underlying and immediate CODs, and demonstrate that the 
majority of deaths (59%) are due to non-cerebral neoplasms (48% of which were not the cause of 
the person’s epilepsy), cardiovascular and cerebrovascular disease while epilepsy-related causes 
account for only 3% of deaths. We demonstrate that pneumonia is the most important immediate 
COD, representing what is likely a common terminus in a morbid sequence of events. Second, 
we demonstrate that overall 23% of underlying CODs are directly related to an individual’s 
epilepsy aetiology and that this is four-fold more likely to be the case if death occurs within two 
years of the index seizure. Third, we demonstrate that certain somatic and psychiatric 
comorbidities are predictive of mortality among PWE. When categorized by ICD-10 chapter: 
neoplasms, endocrine, nutritional and metabolic diseases, congenital malformations, 
deformations and chromosomal abnormalities as well as injury, poisoning and external causes 
are associated with an increased risk of death while diseases of the musculoskeletal system and 
connective tissue are associated with decreased risk. When examining specific conditions, 
primary cerebral and non-cerebral neoplasms, substance abuse, dementia, Parkinson’s disease, 
cerebrovascular disease and traumatic brain injury were independently associated with increased 
mortality risk.  
A number of studies have described an overall increased risk of premature mortality 
among PWE relative to people without epilepsy.
2-7
 Previous analyses of the NGPSE have 
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reported elevated SMRs, most recently reporting an overall standardized mortality ratio (SMR) 
of 2.2 (95% CI: 2.0, 2.5), an increase in premature mortality that was evident even 25 years after 
the index seizure.
1
 That said, the reasons for this increase in mortality remain unclear and 
warrant urgent investigation.  
The majority of deaths in our cohort were due to non-cerebral neoplasms, cardiovascular 
and cerebrovascular disease while relatively few were epilepsy-related. It is difficult to compare 
PMRs between populations given that it is not possible to control for differences in age, sex and 
calendar time. That said, our findings are generally similar to others in high-income countries, 
where a previous meta-analysis reported that 4% of deaths in low-risk groups of PWE are due to 
SUDEP,
28
 but are remarkably different from studies limited to low or middle-income countries 
where approximately 20 to 75% of deaths are due to status epilepticus or SUDEP.
9, 29
 This likely 
reflects the high proportion of idiopathic/cryptogenic epilepsy, ready access to necessary AEDs 
as well as the high proportion of seizure remission 
30
 seen in high-income relative to low or 
middle-income countries, the absence of all of which have both been associated with an 
increased risk of SUDEP.
27, 28
   
Only one other study has investigated the relationship between epilepsy aetiology and 
COD, showing that after one year of follow-up, 72.2% (39 of 54) of CODs among those with 
remote symptomatic epilepsy were related to the underlying epilepsy aetiology.
14
 Thanks to our 
much longer period of follow-up, we have additionally shown that this likelihood is significantly 
greater in the case of early deaths (i.e. within two years of the index seizure) versus those that 
occur later. 
 We report a number of comorbid conditions that significantly and independently 
predicted mortality in the NGPSE, including: both primary cerebral and non-cerebral neoplasms, 
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a history of substance abuse, dementia, Parkinson’s disease, cerebrovascular disease and 
traumatic brain injury. One recent study reported that a lifetime history of any psychiatric 
disorders (including substance abuse) predicted increased risk of death from external causes 
(largely suicide and other accidents).
11
 We did not examine for predictors of external causes of 
death but demonstrate that a lifetime history of substance abuse was a significant predictor of not 
only external causes of death but all-cause mortality. 
Our study has a number of strengths. The NGPSE is a community-based cohort where 
participants were recruited from GP practices across the UK, allowing for a complete spectrum 
of PWE, and has an exceptionally long, almost 25-year period of follow-up. Our method of 
assessing whether an individual has died or not likely captured all deaths. Finally, we carefully 
defined underlying and immediate COD for each participant, using rules as described by the 
World Health Organisation, which is an important distinction if one’s ultimate goal is to interrupt 
the sequence of morbid events leading to death.
20
  
Our study has limitations. The NGPSE relied upon GP reporting of psychiatric and 
somatic comorbidities during the course of 12 different sampling periods between participant 
recruitment and 2001. It is possible that GP reporting was not complete. Since all of our 
comorbidity data were reported prior to anyone’s death, misclassification of each subject’s 
comorbidity status was likely independent (i.e. non-differential) to their eventual survival 
outcome. As a result, any bias would have led to an under-estimation of the associated risk and 
not over-estimation. The NGPSE also relied upon the history and records provided by GPs in the 
1980s to establish the aetiology of each person’s epilepsy without the benefit of modern imaging 
techniques. This likely means that some individuals labelled as having cryptogenic epilepsy 
would have a declared aetiology if the study were repeated today. Practically speaking, however, 
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this eventuality seems unlikely given the current research environment and requirements for 
individual consent, at least in the UK. 
This study presents a number of important findings related to improving our 
understanding of the determinants of premature mortality among PWE. These findings represent 
important opportunities for future research and potential avenues to intervene in the morbid 
sequence of events that may lead to death.  
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TABLES 
Table 1: Study subject characteristics (n=558) 
Characteristic Result
a 
Male sex 291 (52) 
Early epilepsy remission
b 
183 (32) 
All-cause mortality 190 (34) 
Age at index seizure (years) 
Entire cohort 
Alive 
Dead 
 
24.4 (13.8, 56.1) 
17.1 (9.6, 27.4) 
64.2 (50.8, 75.1) 
Age at last follow up (years) 
Entire cohort 
Alive 
Dead 
 
47.4 (36.8, 70.9) 
40.9 (33.3, 51.1) 
74.8 (59.1, 83.1) 
Duration of follow-up (years) 
Entire cohort 
Alive 
Dead 
 
23.0 (14.9, 24.2) 
23.9 (23.0, 24.7) 
8.1 (2.3, 15.2) 
a
 Categorical variables are presented as n (%) while continuous variables are presented as median 
(IQR)
 
b 
Defined as no recurrent seizures more than 1 year after the index event 
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Table 2: Predictors of mortality (n=558) 
Predictor Simple model
a 
Fully adjusted model
a,b 
 Hazard ratio 
(95%CI) 
p-
value 
Hazard ratio 
(95%CI) 
p-
value 
Age at index seizure (years)     
<15 (n=161) Reference . Reference . 
15 to <30 (n=152) 1.56 (0.67, 3.66) 0.302 1.75 (0.74, 4.14) 0.199 
30 to <60 (n=123) 9.55 (4.70, 19.39) <0.001 10.68 (5.18, 
22.01) 
<0.001 
≥60 (n=122) 52.69 (26.46, 
104.92) 
<0.001 66.92 (32.55, 
137.59) 
<0.001 
Male sex (n=291) 0.77 (0.58, 1.03) 0.077 0.69 (0.51, 0.93) 0.013 
Early seizure remission
c
 (n=183) 0.95 (0.73, 1.22) 0.677 0.84 (0.65, 1.09) 0.198 
ICD chapters 
1 – Certain infectious and parasitic diseases (n=11) 1.62 (0.22, 11.88) 0.633   
2 – Neoplasms (n=55) 3.05 (1.67, 5.57) <0.001 2.62 (1.42, 4.82) 0.002 
3 – Diseases of the blood and blood-forming organs 
and certain disorders involving the immune 
mechanism (n=15) 
1.36 (0.60, 3.11) 0.461   
4 – Endocrine, nutritional and metabolic diseases 
(n=41) 
3.10 (1.54, 6.21) 0.001 3.34 (1.64, 6.78) 0.001 
5 – Mental and behavioural disorders (n=135) 1.19 (0.77, 1.83) 0.429   
6 – Diseases of the nervous system (n=83) 1.29 (0.68, 2.46) 0.437   
7 – Diseases of the eye and adnexa (n=12) 0.47 (0.11, 1.90) 0.286   
8 – Diseases of the ear and mastoid process (n=9) n/ad .   
9 – Diseases of the circulatory system (n=119) 1.09 (0.68, 1.75) 0.710   
10 – Diseases of the respiratory system (n=54) 1.27 (0.59, 2.73) 0.539   
11 – Diseases of the digestive system (n=37) 1.49 (0.82, 2.71) 0.188   
12 – Diseases of the skin and subcutaneous tissue 
(n=26) 
1.10 (0.27, 4.48) 0.893   
13 – Diseases of the musculoskeletal system and 
connective tissue (n=32) 
0.46 (0.21, 0.99) 0.048 0.42 (0.19, 0.91) 0.028 
14 – Diseases of the genitourinary system (n=18) 1.09 (0.40, 2.95) 0.872   
15 – Pregnancy, childbirth and the puerperium (n=7) n/ad .   
16 – Certain conditions originating in the perinatal 
period (n=10) 
3.35 (0.78, 14.4) 0.105   
17 – Congenital malformations, deformations and 
chromosomal abnormalities (n=13) 
4.84 (1.92, 12.18) 0.001 5.43 (2.15, 13.75) <0.001 
18 – Symptoms, signs and abnormal clinical and 
laboratory findings, not elsewhere classified (n=13) 
1.84 (0.68, 4.97) 0.229   
19/20 – Injury, poisoning and certain other 
consequences of external causes / External causes of 
morbidity and mortality 
(n=45) 
2.62 (1.21, 5.69) 0.015 2.72 (1.23, 6.00) 0.013 
a 
All models included age at index seizure and sex as covariates.  
b
 This model also included early seizure remission as well as any ICD-10 chapter that was found 
to have a p-value <0.10 in the simple models 
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c 
Defined as no recurrent seizures more than 1 year after the index event 
d 
Not available; could not be calculated due to collinearity  
 19 
 
Table 3: Expanded ICD-10 chapters as predictors of mortality (n=558) 
Predictor Simple model
a 
Fully adjusted model
a,b 
 Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value 
Age at index seizure (years)     
<15 (n=161) Reference . Reference . 
15 to <30 (n=152) 1.56 (0.67, 3.66) 0.302 1.99 (0.83, 4.77) 0.122 
30 to <60 (n=123) 9.55 (4.70, 19.39) 0.001 11.34 (5.38, 23.90) <0.001 
≥60 (n=122) 52.69 (26.46, 104.92) <0.001 59.16 (27.79, 125.97) <0.001 
Male sex (n=291) 0.77 (0.58, 1.03) 0.077 0.70 (0.52, 0.95) 0.023 
Early seizure remission
c
 (n=183) 0.95 (0.73, 1.22) 0.677 0.89 (0.68, 1.16) 0.393 
ICD chapter 2     
Primary cerebral neoplasm (n=22) 4.36 (2.65, 7.17) <0.001 5.42 (3.24, 9.06) <0.001 
Non-cerebral neoplasm (n=34) 3.08 (1.68, 5.65) <0.001 4.04 (2.17, 7.55) <0.001 
ICD chapter 4     
Diabetes mellitus, obesity or 
hypercholesterolemia (n=30) 
2.77 (1.21, 6.39)  0.016 1.22 (0.43, 3.42) 0.708 
Other (n=14) 2.77 (1.11, 6.95) 0.029 2.03 (0.66, 6.22) 0.213 
ICD chapter 5     
Depression (n=42) 0.55 (0.26, 1.19) 0.131   
Anxiety (n=11) 1.09 (0.26, 4.46) 0.909   
Substance abuse (n=27) 3.63 (1.33, 9.88) 0.012 4.86 (1.74, 13.56) 0.003 
Dementia (n=41) 2.30 (1.32, 4.00) 0.003 2.84 (1.56, 5.17) 0.001 
Learning disability (n=22) 2.58 (1.11, 6.03) 0.028 2.21 (0.90, 5.43) 0.083 
Other (n=20) 1.65 (0.21, 12.88) 0.630   
ICD chapter 6     
Migraine (n=30) 1.77 (0.76, 4.10) 0.186   
Parkinson’s disease (n=8) 3.53 (1.40, 8.88) 0.007 4.59 (1.81, 11.68) 0.001 
Focal neurological deficit (n=11) 1.05 (0.14, 7.57) 0.964   
Other (n=34) 0.95 (0.35, 2.61) 0.926   
ICD chapter 9     
Cerebrovascular disease (n=53) 2.93 (1.47, 5.83) 0.002 4.30 (2.13, 8.71) <0.001 
Cardiac disease (n=45) 1.13 (0.65, 1.96) 0.674   
Hypertension (n=37) 1.10 (0.44, 2.74 0.843   
Other (n=20) 1.46 (0.68, 3.14) 0.9184   
ICD chapter 13     
Inflammatory musculoskeletal 
disease (n=14) 
0.23 (0.03, 1.62) 0.139   
Degenerative musculoskeletal 
disease (n=13) 
0.55 (0.22, 1.35) 0.190   
Other (n=5) 0.94 (0.13, 6.80) 0.951   
ICD chapter 17 4.84 (1.92, 12.18) 0.001 5.00 (1.89, 13.22) 0.001 
ICD chapter 19/20     
Traumatic brain injury (n=32) 5.67 (1.34, 23.98) 0.018 9.09 (2.13, 38.72) 0.003 
Any fracture without brain injury 
(n=9) 
2.52 (0.92, 6.90) 0.073 2.34 (0.82, 6.70) 0.112 
Other (n=4) 1.27 (0.17, 9.22) 0.816   
a 
All models included age at index seizures and sex as covariates 
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b 
This model also included early seizure remission as well as any ICD-10 chapter that was found 
to have a p-value <0.10 in the simple models  
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FIGURE LEGENDS 
Figure 1: Proportionate mortality ratio for underlying (A) and immediate (B) causes of death 
Figure 2: Proportionate mortality ratio, stratified by timing of death (A) as well as age at time of 
index seizure (B) and death (C)
 
Legend: * Statistically significant difference with Holms-Bonferroni-corrected p-value <0.05 
Figure 3: Relationship between epilepsy aetiology and underling cause of death 
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SUPPLEMENTARY MATERIAL 
Supplementary Table 1: Underlying cause of death, stratified by timing and age (n=189)
a 
Underlying cause of death Proportionate 
mortality (%) 
Percent 
difference 
p-value
b 
Non-cerebral neoplasm    
Overall (n=189) 21.7   
Death ≤2 years after index seizure (n=40) 32.5 13.7 0.747 
Death >2 years after index seizure (n=149) 18.8 
Aged ≤60 years at time of index seizure (n=73) 26.0 7.0 1.000 
Aged >60 years at time of index seizure (n=116) 19.0 
Aged ≤60 years at time of death (n=47) 17.0 -6.2 1.000 
Aged >60 years at time of death (n=142) 23.2 
Cardiovascular disease    
Overall (n=189) 19.6   
Death ≤2 years after index seizure (n=40) 10.0 -12.1 0.920 
Death >2 years after index seizure (n=149) 22.1 
Aged ≤60 years at time of index seizure (n=73) 13.7 -9.6 0.798 
Aged >60 years at time of index seizure (n=116) 23.3 
Aged ≤60 years at time of death (n=47) 10.6 -11.9 0.546 
Aged >60 years at time of death (n=142) 22.5 
Cerebrovascular disease    
Overall (n=189) 17.5   
Death ≤2 years after index seizure (n=40) 20.0 3.2   1.000 
Death >2 years after index seizure (n=149) 16.8 
Aged ≤60 years at time of index seizure (n=73) 2.7 -24.0 <0.010 
Aged >60 years at time of index seizure (n=116) 26.7 
Aged ≤60 years at time of death (n=47) 4.3 -17.5 0.028 
Aged >60 years at time of death (n=142) 21.8 
Other    
Overall (n=189) 13.2   
Death ≤2 years after index seizure (n=40) 7.5 -7.3 1.000 
Death >2 years after index seizure (n=149) 14.8 
Aged ≤60 years at time of index seizure (n=73) 13.7 0.8 1.000 
Aged >60 years at time of index seizure (n=116) 12.9 
Aged ≤60 years at time of death (n=47) 10.6 -3.5 1.000 
Aged >60 years at time of death (n=142) 14.1 
Primary cerebral neoplasm    
Overall (n=189) 6.3   
Death ≤2 years after index seizure (n=40) 12.5 7.8 0.938 
Death >2 years after index seizure (n=149) 4.7 
Aged ≤60 years at time of index seizure (n=73) 15.1 14.2 <0.010 
Aged >60 years at time of index seizure (n=116) 0.9 
Aged ≤60 years at time of death (n=47) 21.3 19.9 <0.010 
Aged >60 years at time of death (n=142) 1.4 
Pneumonia or pulmonary embolism NOS    
Overall (n=189) 6.3   
Death ≤2 years after index seizure (n=40) 0.0 -8.1 0.740 
Death >2 years after index seizure (n=149) 8.1 
Aged ≤60 years at time of index seizure (n=73) 8.1 1.2 1.000 
Aged >60 years at time of index seizure (n=116) 6.9 
 27 
 
Aged ≤60 years at time of death (n=47) 4.3 -2.7 1.000 
Aged >60 years at time of death (n=142) 7.0 
External causes    
Overall (n=189) 4.2   
Death ≤2 years after index seizure (n=40) 5 1.0  1.000 
Death >2 years after index seizure (n=149) 4 
Aged ≤60 years at time of index seizure (n=73) 8.2 6.5 0.399 
Aged >60 years at time of index seizure (n=116) 1.7 
Aged ≤60 years at time of death (n=47) 12.8 11.4 0.027 
Aged >60 years at time of death (n=142) 1.4 
Congenital neurological disorder    
Overall (n=189) 4.2   
Death ≤2 years after index seizure (n=40) 2.5 -2.2 1.000 
Death >2 years after index seizure (n=149) 4.7 
Aged ≤60 years at time of index seizure (n=73) 9.6 8.7 0.048 
Aged >60 years at time of index seizure (n=116) 0.9 
Aged ≤60 years at time of death (n=47) 12.8 11.4 0.027 
Aged >60 years at time of death (n=142) 1.4 
Neurodegenerative diseases    
Overall (n=189) 3.7   
Death ≤2 years after index seizure (n=40) 7.5 4.8 0.990 
Death >2 years after index seizure (n=149) 2.7 
Aged ≤60 years at time of index seizure (n=73) 1.4 -3.8 1.000 
Aged >60 years at time of index seizure (n=116) 5.2 
Aged ≤60 years at time of death (n=47) 0 -4.9 0.820 
Aged >60 years at time of death (n=142) 4.9 
Epilepsy-related    
Overall (n=189) 3.2   
Death ≤2 years after index seizure (n=40) 2.5 -0.9 1.000 
Death >2 years after index seizure (n=149) 3.4 
Aged ≤60 years at time of index seizure (n=73) 4.1 1.5 1.000 
 Aged >60 years at time of index seizure (n=116) 2.6 
Aged ≤60 years at time of death (n=47) 6.4 4.3 0.820 
Aged >60 years at time of death (n=142) 2.1 
a
 Of 190 deaths, one death certificate was missing and so the cause of death could not be 
determined 
b 
Holms-Bonferroni corrected p-values 
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Supplementary Table 2: Relationship between underlying cause of death and epilepsy, 
stratified by timing of death (n=189)
a 
Number of years 
between index 
seizure and death 
(n) 
Number of deaths 
directly related to 
epilepsy aetiology 
(%) 
Number of epilepsy-
related or deaths or 
due to external 
causes (%)
 
Number of deaths 
not related to 
epilepsy aetiology 
(%) 
Number of people 
with 
idiopathic/cryptoge
nic epilepsy (%)
b 
0-2 (40) 23 (57.5) 3 (7.5) 7 (17.5) 7 (17.5) 
>2-5 (33) 8 (24.2) 4 (12.1) 7 (21.2) 14 (42.4) 
>5-10 (36) 4 (11.1) 1 (2.8) 11 (30.6) 20 (55.6) 
>10-15 (30) 5 (16.7) 1 (3.3) 7 (23.3) 17 (56.7) 
>15 (50) 3 (6.0) 5 (10.0) 10 (20.0) 32 (64.0) 
a
 Of 190 deaths, one death certificate was missing and so cause of death could not be determined 
b
 The relationship between the underlying cause of death and epilepsy aetiology could not be 
determined given that the epilepsy aetiology was unknown   
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Supplementary Table 3: Epilepsy aetiology among subjects who have died as of 5 October 
2009 for whom data was available (n=189)
a
 
 
a 
This is the number of deaths where the death certificate was available. The epilepsy aetiology 
of the one individual with a missing death certificate was alcohol-related 
 
 
  
Aetiology n (%) 
Cerebrovascular 
Neoplasm 
EtOH or drug abuse 
Post traumatic 
Congenital or genetic 
Other 
Post encephalitis 
Perinatal injury 
 
Unknown/idiopathic 
61 (32.3) 
21 (11.1) 
4 (2.1)
 
3 (1.6) 
6 (3.2) 
1 (0.5) 
1 (0.5) 
1 (0.5) 
 
91 (48.2) 
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